Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications

Haruki,Tomohiro; Shomori,Kohei; Shiomi,Tatsushi; Taniguchi,Yuji; Nakamura,Hiroshige; Ito,Hisao

doi:10.3892/or.2012.1894

Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications

Authors:
- Tomohiro Haruki
- Kohei Shomori
- Tatsushi Shiomi
- Yuji Taniguchi
- Hiroshige Nakamura
- Hisao Ito
View Affiliations

Affiliations: Division of Organ Pathology, Department of Microbiology and Pathology, Faculty of Medicine, Tottori University, Yonago-city, Tottori 683-8503, Japan, Division of General Thoracic Surgery, Tottori University Hospita, Yonago-city, Tottori 683-8504, Japan
Published online on: July 3, 2012 https://doi.org/10.3892/or.2012.1894
Pages: 915-922

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cell cycle-related molecules play crucial roles in maintaining genomic stability, and can also serve as biomarkers of cell cycle phase distribution at the same time. In this study, we used multiparameter analysis of various biomarkers to investigate their utility for the evaluation of tumor proliferation activities and the prognosis of patients with small-size lung adenocarcinoma. We performed immunohistochemical analysis using five cell cycle-related biomarkers (MCM7, Ki-67, Geminin, Aurora A and H3S10ph) for 102 surgically resected small-size lung adenocarcinomas. We classified them into three phenotypes based on the dominant cell cycle phase distribution of the tumor cell population, and evaluated whether these phenotypes were associated with clinicopathological factors and survival. Phenotype I (MCM7-negative tumors; n=56) was correlated with high or moderate differentiation and reduced local invasiveness (pleural and lymphovascular invasion) compared with phenotype II (MCM7-, Ki-67- and Geminin-positive tumors; n=23) and phenotype III (MCM7-, Aurora A- and H3S10ph-positive tumors; n=17). Five-year survival rates of phenotypes I, II and III were 89.8, 55.4 and 38.6%, respectively, with a significant difference between them (p<0.01). Multivariate analysis revealed that phenotypes II and III were independent prognostic factors in the 79 patients with stage I lung adenocarcinoma. Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma provided novel insights into the cell cycle phase distribution of dynamic tumor cell populations in vivo; it may be possible to evaluate tumor proliferation activities and patient prognosis more precisely if this analytical procedure is used.

View Figures

View References

1	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: pp. 12–44. 2004
2	Louis DN, Edgerton S, Thor AD and Hedley-Whyte ET: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol. 81:675–679. 1991.
3	Mehdi SA, Etzell JE, Newman NB, Weidner N, Kohman LJ and Graziano SL: Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer. 20:99–108. 1998.
4	Haga Y, Hiroshima K, Iyoda A, et al: Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg. 75:1727–1732. 2003.
5	Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF and Williams GH: Mcm2, Geminin, and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 11:2510–2517. 2005.
6	Vargas PA, Cheng Y, Barrett AW, Craig GT and Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med. 37:309–318. 2008.
7	Fujioka S, Shomori K, Nishihara K, et al: Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): prognostic implication. Lung Cancer. 65:223–229. 2009.
8	Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E and Ito H: MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology. 71:193–200. 2004.
9	Kulkarni AA, Loddo M, Leo E, et al: DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res. 13:6153–6161. 2007.
10	Loddo M, Kingsbury SR, Rashid M, et al: Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer. 100:959–970. 2009.
11	Kayes OJ, Loddo M, Patel N, et al: DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res. 15:7335–7344. 2009.
12	Nishitani H and Lygerou Z: Control of DNA replication licensing in a cell cycle. Genes Cells. 7:523–534. 2002.
13	Pitulescu M, Kessel M and Luo L: The regulation of embryonic patterning and DNA replication by geminin. Cell Mol Life Sci. 62:1425–1433. 2005.
14	Tamura T, Shomori K, Haruki T, et al: Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. J Oral Pathol Med. 39:328–334. 2010.
15	Torres-Rendon A, Roy S, Craig GT and Speight PM: Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer. 100:1128–1134. 2009.
16	Nishihara K, Shomort K, Fujioka S, et al: Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance. Int J Oncol. 33:245–251. 2008.
17	Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T and Ito H: Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. Oncol Rep. 21:1189–1195. 2009.
18	Tokuyasu N, Shomori K, Nishihara K, et al: Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance. Gastric Cancer. 11:37–46. 2008.
19	Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32. 2001.
20	Crosio C, Fimia GM, Loury R, et al: Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 22:874–885. 2002.
21	Bischoff JR, Anderson L, Zhu Y, et al: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998.
22	Jeng YM, Peng SY, Lin CY and Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 10:2065–2071. 2004.
23	Kurahashi T, Miyake H, Hara I and Fujisawa M: Significance of Aurora-A expression in renal cell carcinoma. Urol Oncol. 25:128–133. 2007.
24	Lam AK, Ong K and Ho YH: Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Hum Pathol. 39:599–604. 2008.
25	Ogawa E, Takenaka K, Katakura H, et al: Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small cell lung cancer (NSCLC). Ann Surg Oncol. 15:547–554. 2008.
26	Shang X, Burlingame SM, Okcu MF, et al: Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther. 8:2461–2469. 2009.
27	Tanaka E, Hashimoto Y, Ito T, et al: The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res. 11:1827–1834. 2005.
28	Zhang XH, Rao M, Loprieato JA, et al: Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther. 7:1390–1399. 2008.
29	Williams GH and Stoeber K: Cell cycle markers in clinical oncology. Curr Opin Cell Biol. 19:672–679. 2007.
30	Sobin LH: UICC International Union Against Cancer: TNM classification of malignant tumours. 6th edition. John Wiley & Sons; New York: 2002
31	Suzuki K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Nagai K and Nishiwaki Y: Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 69:893–897. 2000.
32	Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED and Williams GH: DNA replication licensing and human cell proliferation. J Cell Sci. 114:2027–2041. 2001.
33	Blow JJ and Hodgson B: Replication licensing - defining the proliferative state? Trends Cell Biol. 12:72–78. 2002.
34	Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH and Coleman N: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 5:2121–2132. 1999.
35	Gonzalez MA, Tachibana KK, Laskey RA and Coleman N: Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer. 5:135–141. 2005.
36	Montanari M, Macaluso M, Cittadini A and Giordano A: Role of geminin: from normal control of DNA replication to cancer formation and progression? Cell Death Differ. 13:1052–1056. 2006.
37	Gonzalez MA, Tachibana KE, Chin SF, et al: Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol. 204:121–130. 2004.
38	Marumoto T, Zhang DW and Saya H: Aurora-A: a guardian of poles. Nat Rev Cancer. 5:42–50. 2005.
39	Tong T, Zhong Y, Kong J, et al: Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res. 10:7304–7310. 2004.
40	Royce ME, Xia WY, Sahin AA, et al: STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer. 100:12–19. 2004.
41	Johnson KR, Wang L, Miller MC III, et al: 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res. 3:1739–1745. 1997.